Skip to main content
1 minute reading time (104 words)

Expert Guidance on New Advances in Renal Cell Carcinoma With Bradley McGregor, MD and Robert Motzer, MD

Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at diagnosis, which is associated with poor outcomes. The 5-year survival rate for patients with regional RCC is only 70% and drops to a dismal 12% for those with distant metastases (ACS, 2020).

Related Posts